Home News CAR-T vs. bispecifics for lymphoma: Using the evidence to sequence treatments back to News
minute read
Curative potential at a longer follow-up, logistics and patient risk and eligibility are all important considerations when sequencing bispecific antibodies and chimeric antigen receptor T-cell therapy for advanced large B-cell lymphoma.
Topics: Press Coverage
12631 East 17th Avenue
8601
Aurora, CO 80045
303-724-1785
© 2024 The Regents of the University of Colorado, a body corporate. All rights reserved.
Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.
